| Primary information |
|---|
| sequence ID | Seq_4944 |
| Peptide sequence | LMIEQNTKSPLFMGKVVNPTQK |
| CancerPDF_ID | CancerPDF_ID64, CancerPDF_ID3751, CancerPDF_ID10591, |
| PMID | 16896061,27026199,21805675 |
| Protein Name | Alpha-1-antitrypsin precursor,Alpha-1-antitrypsin,Alpha-1-antitrypsin |
| UniprotKB Entry Name | A1AT_HUMAN,A1AT_HUMAN,A1AT_HUMAN |
| Fluid | Serum,Urine,Urine |
| M/Z | 835.16,NA,2503.3475 |
| Charge | 1,NA,NA |
| Mass (in Da) | 2503.33,NA,NA |
| fdr | NA,2502.32,NA |
| Profiling Technique | MALDI-TOF,"CE-MS, Micro-TOF-MS",MALDI-TOF |
| Peptide Identification technique | Q/TOF MS/MS,MS-MS,MALDI-TOF-MS |
| Quantification Technique | NA,NA,NA |
| Labelled/Label Free | Label Free,Label Free,Label Free |
| FDR | NA,NA,1 |
| CancerPDF_ID | CancerPDF_ID64, CancerPDF_ID3751, CancerPDF_ID10591, |
| p-Value | 1.00E-05,less than 0.05,NA |
| Software | MASCOT,Proteome Discoverer 1.2,NA |
| Length | 22,22,22 |
| Cancer Type | Metastatic thyroid carcinomas,Bladder cancer,Muscle-invasive bladder cancer |
| Database | NCBI refseq Protein Database,Uniprot Human non-redundant Database,SwissProt Database |
| Modification | NA,NA,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation, 425 for training(109 patients with Recurrent UBC cases and 316 negative for recurrence controls) and 211 for validation (55 UBC recurrent cases and 156 recurrent controls),751 bladder cancer and 127 control |
| Regulation | NA,Differentially expressed between recurrence of UBC vs recurrence control,Differentially expressed between cancer vs normal samples |
| Validation | Independent validation,Independent Validation,Mann-Whitney tests and areas under receiver-operator characteristic |
| Sensitivity | 95% on independent dataset,For testing dataset 88%,NA |
| Specificity | 95% on independent dataset,For testing dataset 51%,NA |
| Accuracy | NA,NA,NA |
| Peptide Atlas | NA |
| IEDB | |